The ureteric bud (UB) is a kidney precursor tissue that repeats branching morphogenesis and gives rise to the collecting ducts (CDs) and lower urinary tract. Here, we describe protocols to generate iUB organoids from human iPSCs; iUB organoids repeat branching morphogenesis. We describe how to expand iUB-organoid-derived tip colonies and how to induce CD progenitors from iUB organoids. These organoids can be used to study CD development and potentially as a model of kidney and urinary tract diseases.

Publisher's note: Undertaking any experimental protocol requires adherence to local institutional guidelines for laboratory safety and ethics.
Protocol
 Protocol for the generation and expansion of human iPS cell-derived ureteric bud organoids

Makoto Ryosaka,1,2,3 Shin-Ichi Mae,1,3,4 and Kenji Osafune1,5,*

1Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
2Rege Nephro Co., Ltd., Med-Pharm Collaboration Building, Kyoto University, 46-29 Yoshidashimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan
3These authors contributed equally
4Technical contact
5Lead contact
*Correspondence: osafu@cira.kyoto-u.ac.jp
https://doi.org/10.1016/j.xpro.2022.101484

SUMMARY
The ureteric bud (UB) is a kidney precursor tissue that repeats branching morphogenesis and gives rise to the collecting ducts (CDs) and lower urinary tract. Here, we describe protocols to generate iUB organoids from human iPSCs; iUB organoids repeat branching morphogenesis. We describe how to expand iUB-organoid-derived tip colonies and how to induce CD progenitors from iUB organoids. These organoids can be used to study CD development and potentially as a model of kidney and urinary tract diseases.
For complete details on the use and execution of this protocol, please refer to Mae et al. (2020).

BEFORE YOU BEGIN

Note: All procedures in this protocol are performed in a Class II biological hood according to standard aseptic technique. Cells are cultured in a humidified 37°C incubator at 5% CO2.

Institutional permissions

† Timing: up to 2 days

Any animal experiments must be approved by the institutional animal care committee. Any experiments using human induced pluripotent stem cells (hiPSCs) must be approved by the institutional ethics committee and informed consent must be obtained from donors from whom hiPSCs were derived.

1. Preparation of stock solutions and aliquots.

Reconstitute the chemical compounds and growth factors according to the manufacturer’s recommendation and aliquot for storage (see materials and equipment for details).
# Key Resources Table

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| Mouse anti-AQP2 (1:200) | Santa Cruz | Cat#ab-515770; RRID: AB_2810957 |
| Goat anti- BRACHYURY (1:500) | R&D | Cat#ab-2810957 |
| Mouse anti-CK8 (1:500) | Abcam | Cat#ab-9023; RRID: AB_306948 |
| Mouse anti-E-CADHERIN (1:500) | BD | Cat#610181; RRID: AB_397580 |
| Goat anti-E-CADHERIN (1:200) | R&D | Cat#ab-2200235 |
| Mouse anti-EZRIN (1:500) | Abcam | Cat#Ab4069; RRID: AB_304261 |
| Mouse anti-FOXA1 (1:500) | Santa Cruz | Cat#ab-514695 |
| Rabbit anti-GATA3 (1:500) | Cell Signaling | Cat#58525; RRID: AB_10835690 |
| Goat anti-GATA3 (1:100) | R&D | Cat#ab-2605; RRID: AB_2108571 |
| Rabbit anti-LAMININ (1:500) | Sigma | Cat#L9393-2ML; RRID: AB_477163 |
| Rabbit anti-PAX2 (1:500) | BioLegend | Cat#PRB-276P; RRID: AB_291611 |
| Goat anti-PAX2 (1:500) | R&D | Cat#ab-3364; RRID: AB_10889828 |
| Rabbit anti-PRKCI (1:200) | Santa Cruz | Cat#ab-316; RRID: AB_2300359 |
| Goat anti-RET (1:500) | R&D | Cat#ab-1485; RRID: AB_354820 |
| Donkey anti-Mouse IgG- Alexa Fluor 488 (1:500) | Thermo Fisher Scientific | Cat#ab-21020; RRID: AB_141607 |
| Donkey anti-Rabbit IgG- Alexa Fluor 488 (1:500) | Thermo Fisher Scientific | Cat#ab-21066; RRID: AB_2535792 |
| Donkey anti-Goat IgG- Alexa Fluor 488 (1:500) | Thermo Fisher Scientific | Cat#ab-11055; RRID: AB_2534102 |
| Donkey anti-Mouse IgG- Alexa Fluor 546 (1:500) | Thermo Fisher Scientific | Cat#ab-10036; RRID: AB_2534012 |
| Donkey anti-Rabbit IgG- Alexa Fluor 546 (1:500) | Thermo Fisher Scientific | Cat#ab-10040; RRID: AB_2534016 |
| Donkey anti-Goat IgG- Alexa Fluor 546 (1:500) | Thermo Fisher Scientific | Cat#ab-11056; RRID: AB_2534103 |
| Donkey anti-Mouse IgG- Alexa Fluor 647 (1:500) | Thermo Fisher Scientific | Cat#ab-31571; RRID: AB_162542 |
| Donkey anti-Rabbit IgG- Alexa Fluor 647 (1:500) | Thermo Fisher Scientific | Cat#ab-31573; RRID: AB_2536183 |
| Donkey anti-Goat IgG- Alexa Fluor 647 (1:500) | Thermo Fisher Scientific | Cat#ab-21447; RRID: AB_2536183 |
| Hoechst 33342 (1:500) | Thermo Fisher Scientific | Cat#H1399 |
| **Chemicals, peptides, and recombinant proteins** | | |
| AB3-01 | Wakao | 035-24113 |
| 30% w/v Albumin D-PBS(-) Solution, from Bovine Serum (BSA), Fatty Acid Free | Wakao | 015-23871 |
| Accutase | Innovative Cell Technologies | AT104 |
| Actin | R&D | 338-AC |
| Afamin/Wnt3a CM | MBL | J-ORMW301R |
| B-27 Supplement minus vitamin A | Thermo Fisher Scientific | 12587001 |
| Cell Recovery Solution | BD | 354253 |
| CtrlRP9021 | StemRD | CHR-010 |

*(Continued on next page)*
### Preparation and storage of growth factors and small-molecule compounds

Mix 100 μL 30% w/v Albumin D-PBS(-) Solution, from Bovine Serum (BSA), Fatty Acid Free (FUJIFILM) and 29.9 mL D-PBS(-). Collect the solution in a 50-mL syringe and filtrate it through a 0.22 μm filter. Store at 4°C for up to half a year.

#### Activin A
Centrifuge the vial prior to opening. Add 50 mL 0.1% BSA/PBS to 500 μg Activin A to prepare a 10 μg/mL stock. Mix by pipetting up and down. Make a 1 mL aliquot and store at -20°C for up to 1 year.

---

**Materials and Equipment**

**Preparation and storage of growth factors and small-molecule compounds**

0.1% BSA in PBS to prepare stock solutions

Mix 100 μL 30% w/v Albumin D-PBS(-) Solution, from Bovine Serum (BSA), Fatty Acid Free (FUJIFILM) and 29.9 mL D-PBS(-). Collect the solution in a 50-mL syringe and filtrate it through a 0.22 μm filter. Store at 4°C for up to half a year.

### Activin A
Centrifuge the vial prior to opening. Add 50 mL 0.1% BSA/PBS to 500 μg Activin A to prepare a 10 μg/mL stock. Mix by pipetting up and down. Make a 1 mL aliquot and store at -20°C for up to 1 year.
A83-01
Centrifuge the vial prior to opening. Add 474 μL DMSO to 2 mg A83-01 to prepare a 1 mM stock. Mix by pipetting up and down. Make a 100 μL aliquot and store at −20°C for up to 1 year.

Note: You can also use A83-01 from EMD Bioscience (Cat# 616454-2MG).

CHIR99021
Centrifuge the vial prior to opening. Add 2.15 mL DMSO to 10 mg CHIR99021 to prepare a 10 mM stock. Mix by pipetting up and down. Make a 40 μL aliquot and store at −20°C for up to 1 year. To prepare 1 mM and 3 mM CHIR99021 working solution, add 360 μL and 94 μL DMSO, respectively. Store at 4°C for up to 3 months.

Note: You can also use CHIR99021 from Wako (Cat# 038-23101).

EDTA
Add 500 μL UltraPure™ 0.5 M EDTA, pH 8.0, to 500 mL D-PBS(-) Filtrate the mixture through a 0.22 μm filter. Make a 50 mL aliquot and store at 4°C for up to 1 year.

EGF
Centrifuge the vial prior to opening. Add 10 mL 0.1% BSA/PBS to 1 mg EGF to prepare a 100 μg/mL stock. Mix by pipetting up and down. Make a 100 μL aliquot and store at −20°C for up to half a year.

FGF1
Centrifuge the vial prior to opening. Add 125 μL 0.1% BSA/PBS to 25 μg FGF1 to prepare a 200 μg/mL stock. Mix by pipetting up and down. Store at −20°C for up to half a year.

FGF8
Centrifuge the vial prior to opening. Add 5 mL sterile ddH₂O to 1 mg FGF8 to prepare a 200 μg/mL stock. Mix by pipetting up and down. Make a 100 μL aliquot and store at −20°C for up to half a year.

GDNF
Centrifuge the vial prior to opening. Add 100 μL 0.1% BSA/PBS to 10 μg GDNF to prepare a 100 μg/mL stock. Mix by pipetting up and down. Store at −20°C for up to 1 year.

IWR-1
Centrifuge the vial prior to opening. Add 1.22 mL DMSO to 5 mg IWR-1 to prepare a 10 mM stock. Mix by pipetting up and down. Make a 100 μL aliquot and store at −20°C for up to 1 year. To prepare a 1 mM working solution, add 90 μL DMSO to the 10 mL stock solution. Store the working solution at 4°C for up to half a year.

LDN193189
Centrifuge the vial prior to opening. Add 388 μL DMSO to 2 mg LDN193189 to prepare a 10 mM stock. Mix by pipetting up and down. Make a 50 μL aliquot and store at −20°C for up to 1 year. To prepare a 0.1 mM LDN193189 working solution, add 99 μL DMSO to 1 μL of the 10 mM LDN193189 stock solution. Store the working solution at 4°C for up to half a year.

Matrigel
Thaw the Matrigel vial on a 4°C incubator for 24 h. Use precooled tips and precooled reaction tubes to make 2 mg aliquots. Store the aliquots at −20°C. The aliquots are stable for around 1 year (see certificate of analysis for each batch). Before use, thaw the required number of aliquots on ice (takes around 30 min).
Note: Keep Matrigel always on ice and take it out of the ice only when it is to be added to the medium.

Thiazovivin
Centrifuge the vial prior to opening. Add 3.21 mL DMSO to 10 mg Thiazovivin to prepare a 10 mM stock. Mix by pipetting up and down. Make a 50 μL aliquot and store at –20°C for up to 1 year.

TTNPB
Centrifuge the vial prior to opening. Add 2.87 mL DMSO to 10 mg TTNPB to prepare a 10 mM stock. Mix by pipetting up and down. Make a 50 μL aliquot and store at –80°C until the expiry date indicated on the label. To prepare 0.1 mM TTNPB working solution, add 99 μL DMSO to 1 μL 10 mM TTNPB stock solution. Store the working solution at 4°C for up to half a year.

Y-27632
Centrifuge the vial prior to opening. Add 7.39 mL sterile ddH₂O to 25 mg Y-27632 to prepare a 10 mM stock. Mix by pipetting up and down. Make a 400 μL aliquot and store at –20°C for up to 1 year.

R-spondin 1
Centrifuge the vial prior to opening. Add 1 mL 0.1% BSA/PBS to 100 μg R-spondin 1 to prepare a 100 μg/mL stock. Mix by pipetting up and down. Make a 100 μL aliquot and store at –20°C for up to half a year.

Afamin/Wnt3a CM
Thaw Afamin/Wnt3a CM at 4°C for 24 h. Make a 1 mL aliquot and store at –20°C for up to 1 year.

△ CRITICAL: Avoid repeated freeze-thaw cycles.

Culture media

Anterior primitive streak induction medium (APS medium)

| Reagent            | Final concentration | Amount |
|--------------------|---------------------|--------|
| Activin A (10 μg/mL) | 100 ng/mL           | 10 μL  |
| CHIR99021 (3 mM)    | 3 μM                | 1 μL   |
| Essential 6 medium  | n/a                 | 1 mL   |
| Total               | n/a                 | 1 mL   |

n/a: not applicable.

Make APS medium fresh for every use.

Note: 1 mL APS medium is required for two wells of a 4-well culture plate. We use two wells for a regular differentiation experiment.

Anterior intermediate mesoderm induction medium (AIM medium)

| Reagent            | Final concentration | Amount |
|--------------------|---------------------|--------|
| A83-01 (1 mM)      | 1 μM                | 1 μL   |
| TTNPB (100 μM)     | 100 nM              | 1 μL   |
| LDN193189 (0.1 mM) | 0.1 μM              | 1 μL   |
| FGF8 (200 μg/mL)   | 200 ng/mL           | 1 μL   |
| Essential 6 medium | n/a                 | 1 mL   |
| Total               | n/a                 | 1 mL   |

n/a: not applicable.
Make AIM medium fresh for every use.

**Note:** 1 mL AIM medium is required for two wells of a 4- or 24-well culture plate. We use two wells for a regular differentiation experiment.

| Reagent                         | Final concentration | Amount |
|---------------------------------|---------------------|--------|
| CHIR99021 (1 mM)                | 1 μM                | 2 μL   |
| TTNPB (100 μM)                  | 100 nM              | 2 μL   |
| LDN193189 (0.1 mM)              | 0.1 μM              | 2 μL   |
| FGF8 (200 μg/mL)                | 200 ng/mL           | 2 μL   |
| GDNF (100 μg/mL)                | 100 ng/mL           | 2 μL   |
| Essential 6 medium              | n/a                 | 2 mL   |
| Total                           | n/a                 | 2 mL   |

n/a: not applicable.

Make ND medium fresh for every use.

**Note:** 2 mL ND medium is required for two wells of a 24-well culture plate. We use two wells for a regular differentiation experiment.

| Reagent                         | Final concentration | Amount |
|---------------------------------|---------------------|--------|
| CHIR99021 (1 mM)                | 1 μM                | 2 μL   |
| TTNPB (100 μM)                  | 100 nM              | 2 μL   |
| LDN193189 (1 mM)                | 1 μM                | 2 μL   |
| FGF8 (200 μg/mL)                | 200 ng/mL           | 2 μL   |
| GDNF (100 μg/mL)                | 100 ng/mL           | 2 μL   |
| FGF1 (200 μg/mL)                | 200 ng/mL           | 2 μL   |
| EGF (100 μg/mL)                 | 50 ng/mL            | 1 μL   |
| Essential 6 medium              | n/a                 | 2 mL   |
| Matrigel                        | 2% vol              | 40 μL  |
| Total                           | n/a                 | 2 mL   |

n/a: not applicable.

Make UB organoid medium fresh for every use.

**Note:** 2 mL UB organoid medium is required for 20 wells of a 96-well culture plate. We use two wells for a regular differentiation experiment.

⚠️ CRITICAL: Keep Matrigel on ice during the entire process. Before making the UB organoid medium, thaw the required number of Matrigel aliquots on ice for 30 min. Take them out of the ice only when they are to be added to the medium. After adding Matrigel to the medium, you can manipulate the UB organoid medium at around 25°C because the final Matrigel concentration is sufficiently low.
Make the reconstituted UB organoid medium fresh for every use.

**Note:** 2 mL reconstituted UB organoid medium is required for 20 wells of a 96-well culture plate. We regularly use two wells for a differentiation experiment.

⚠ **CRITICAL:** Keep Matrigel on ice during the entire process. Before making the reconstituted UB organoid medium, thaw the required number of Matrigel aliquots on ice for 30 min. Take them out of the ice only when they are to be added to the medium. After adding Matrigel to the medium, you can manipulate the reconstituted UB organoid medium at around 25°C because the final Matrigel concentration is sufficiently low.

### Reconstituted UB organoid medium

| Reagent               | Final concentration | Amount |
|-----------------------|---------------------|--------|
| TTNPB (100 μM)        | 100 nM              | 2 μL   |
| LDN193189 (1 mM)      | 1 μM                | 2 μL   |
| FGF8 (200 μg/mL)      | 200 ng/mL           | 2 μL   |
| GDNF (100 μg/mL)      | 100 ng/mL           | 2 μL   |
| FGF1 (200 μg/mL)      | 200 ng/mL           | 2 μL   |
| EGF (100 μg/mL)       | 50 ng/mL            | 1 μL   |
| Essential 6 medium    | n/a                 | 1.8 mL |
| Matrigel              | 2% vol              | 40 μL  |
| R-spondin1            | 200 ng/mL           | 2 μL   |
| Afamin/Wnt3a CM       | 10% vol             | 200 μL |
| Total                 | n/a                 | 2 mL   |

n/a: not applicable.

Make the UB tip medium fresh for every use.

**Note:** 1.5 mL UB tip medium is required for 5 wells of a 48-well culture plate. We use 5 wells for a regular differentiation experiment.

### UB tip medium

| Reagent               | Final concentration | Amount |
|-----------------------|---------------------|--------|
| CHIR99021 (3 mM)      | 3 μM                | 1.5 μL |
| TTNPB (100 μM)        | 100 nM              | 1.5 μL |
| Thiazovivin (10 mM)   | 10 μM               | 1.5 μL |
| FGF1 (200 μg/mL)      | 200 ng/mL           | 1.5 μL |
| GDNF (100 μg/mL)      | 100 ng/mL           | 1.5 μL |
| B27 supplement        | 2% vol              | 30 μL  |
| DMEM/F12, GlutaMAX    | n/a                 | 1.5 mL |
| Total                 | n/a                 | 1.5 mL |

n/a: not applicable.

### Collecting duct progenitor (CDP) induction medium (CDP medium)

| Reagent               | Final concentration | Amount |
|-----------------------|---------------------|--------|
| IWR1 (1 mM)           | 1 μM                | 2 μL   |
| A83-01 (1 mM)         | 1 μM                | 2 μL   |
| Essential 6 medium    | n/a                 | 2 mL   |
| Total                 | n/a                 | 2 mL   |

n/a: not applicable.
Make the CDP medium fresh for every use.

**Note:** 2 mL CDP medium is required for two wells of a 24-well culture plate. We use two wells for a regular differentiation experiment.

| DMEM/F12 10%FBS | Final concentration | Amount |
|-----------------|---------------------|--------|
| DMEM/F-12, GlutaMAX | n/a | 450 mL |
| Fetal Bovine Serum (FBS) | 10 vol% | 50 mL |
| Total | n/a | 500 mL |

CRITICAL: Store DMEM/F12 10%FBS at 4°C for up to 3 months.

**Note:** After mixing DMEM/F12, GlutaMAX and FBS, filtrate the mixture through a 0.22 μm filter.

| Hydrogel | Final concentration | Amount |
|----------|---------------------|--------|
| DMEM/F-12, GlutaMAX | n/a | 75 μL |
| Matrigel | 50 vol% | 75 μL |

CRITICAL: Keep Matrigel and hydrogel on ice during the entire process. Before making hydrogel, thaw the required number of Matrigel aliquots on ice for 30 min. Take them out of the ice only when they are to be added to the medium. After mixing the medium and Matrigel, you should keep hydrogel on ice to prevent it from solidifying until adding it on the culture plate.

**Note:** Hydrogel is an appropriate culture environment in terms of stiffness for forming UB tip colonies.

**Note:** Hydrogel with sufficient hardness cannot be formed with Geltrex.

**STEP-BY-STEP METHOD DETAILS**

**Maintenance of hiPSCs**

**Timing:** every 4 days

This section describes the maintenance culture of hiPSCs.

1. Maintenance culture.
   a. Maintain the hiPSCs in feeder-free cultures containing Stem Fit AK02N medium on 6-well plates.
   b. Passage the hiPSCs every four days with no more than 80% confluence.
c. To passage the hiPSCs, aspirate the medium and wash the cells with 2 mL EDTA (0.5 mM)/PBS. Add 2 mL EDTA/PBS and incubate the cells at 37°C for 3 min.

⚠ CRITICAL: Extended exposure (> 10 min) to EDTA/PBS will decrease cell viability and differentiation potential when you passage hiPSCs.

d. Aspirate the EDTA/PBS and add 2 mL Stem Fit AK02N. Dissociate the cells into single cells by gentle pipetting.
e. After cell counting, replate the cells at a density of $5 \times 10^4$ cells/well in 6-well plates and add 2 mL Stem Fit AK02N medium containing 10 μM Y-27632 and 0.125 μg/cm² iMatrix-511 silk.

Note: We recommend that maintenance medium for hiPSCs be Stem Fit AK02N or AK03N (Ajinomoto) because the induction efficiency of UB lineage cells may be decrease with hiPSCs maintained in other media, such as Essential 8 (Thermo Fisher Scientific).

Note: We add iMatrix-511 silk to the medium to coat the plate at passaging. You may precoat the plate with iMatrix-511 silk at 37°C for 1 h; however, this is a time-consuming process (Miyazaki et al., 2017).

⚠ CRITICAL: Adding ROCK inhibitor is important to prevent hiPSC apoptosis at passaging.

Preparation of hiPSCs for differentiation

Timing: 1 day for pre-differentiation

This section describes the preparation culture of hiPSCs before differentiation.

2. Pre-differentiation.
   a. Prepare the hiPSC suspension at passaging.
   b. After cell counting, replate the cells at a density of $2.5 \times 10^4$ cells/cm² and add Stem Fit AK02N medium containing 10 μM Y-27632 and 0.125 μg/cm² iMatrix-511 silk.

Note: hiPSCs will be 30%–40% confluency during pre-differentiation.

⚠ CRITICAL: Both confluency and the size of the initial hiPSC colonies should be considered to avoid spontaneous differentiation.

Note: We use two wells of a 4-well culture plate, and the medium volume is 500 μL for a regular differentiation experiment. Other plate formats, such as 24-well plates, can be used alternatively.

⚠ CRITICAL: Adding ROCK inhibitor to the medium is important to prevent apoptosis at pre-differentiation.

c. Incubate the cells at 37°C for 24 h (Figure 1A).

Note: Incubate the cells with EDTA/PBS until the cells have clearly defined bright edges under a brightfield microscope (Figure 1B). The differentiation efficiency might decrease if the cells are treated with EDTA/PBS for >5 min or too short.
**Figure 1. Induction of iUB organoids**

(A) Morphology of hiPSCs 24 h after thawing prior to differentiation.

(B) Morphology of hiPSCs treated with EDTA/PBS for 3 min. The cells must have clearly defined bright edges under a brightfield microscope.

(C) The protocol to differentiate hiPSCs into iUB organoids. APS, anterior primitive streak; AIM, anterior intermediate mesoderm; ND, nephric duct; UB, ureteric bud; A, 100 ng/mL Activin A; C3, 3 μM CHIR99021; F8, 200 ng/mL FGF8; TT, 0.1 μM TTNPB; A83, 1 μM A83-01; LDN, 0.1 μM LDN193189; Y, 10 μM Y-27632; C1, 1 μM Chir99021; G, 100 ng/mL GDNF; F1, 200 ng/mL FGF1; and E, 50 ng/mL EGF.

(D) Immunostaining of day 3 AIM cells for GATA3 (green), LHX1 (red) and nuclei (blue).

(E) Immunostaining of day 2 ND elongation cells for GATA3 (green), RET (red) and nuclei (blue).

(F) A schematic showing a ND aggregate (red) and unwanted cells (blue; left panel) and morphology of a day 2 aggregate before (middle panel) and after (right panel) pipetting to remove unwanted cells. The red circles in the middle and right panels indicate a ND aggregate.

(G) Morphology of a day 6 iUB organoid.

(H) Immunostaining of a day 7 iUB organoid for LAMININ (green), EZRIN (red) and nuclei (blue).

(I) Immunostaining of cryosections of a day 7 iUB organoid for CK8 (green), RET (red) and nuclei (blue).

(J) Morphology of a day 6 iUB organoid (upper panel) and tips separated from day 6 iUB organoids (lower panel).

(K) 3D whole-mount immunostaining of a day 14 separated tip-derived iUB organoid for RET (green) and E-CADHERIN (red). Scale bars, 300 μm in (F) and 100 μm in (A)–(E) and (G)–(J). (J) is adapted from Mae et al. (2020).
Note: We recommend that the maintenance medium for hiPSCs be Stem Fit AK02N or AK03N (Ajinomoto) because the induction efficiency of UB lineage cells may decrease with hiPSCs maintained in other media, such as Essential 8 (Thermo Fisher Scientific).

Nephric duct cell induction in 2D culture

© Timing: 16–28 h for APS induction, 3 days for AIM induction and 2 days for ND elongation

This section describes the induction of nephric duct (ND) cells through APS and AIM steps.

3. APS induction (Figure 1C).
   a. Prepare 1 mL APS medium for two wells of a 4-well plate before starting this step.
   b. After 1 day of pre-differentiation with StemFit AK02N, wash the cells with 500 µL PBS and add 500 µL APS medium per well.
   c. Incubate the cells at 37°C for 16–28 h.

   Note: You may need to optimize the incubation time depending on the hiPSC lines. To confirm APS induction, we recommend bright field microscopic observations and immunostaining analysis. Refer to troubleshooting 1.

4. AIM induction (Figure 1C).
   a. Prepare 3 mL AIM medium before starting this step.
   b. After 16–28 h of APS induction, wash the cells with 500 µL PBS, add 1 mL AIM medium per well and incubate at 37°C for 2 days without changing the medium.
   c. After 2 days, coat the 24-well plates with 300 µL Geltrex per well and incubate at 37°C for 1 h.

   Note: Geltrex is ready-to-use and stored at 4°C until the expiry date indicated on the label. Coat new 24-well plates with undiluted Geltrex. You can use Matrigel alternatively.
   d. Aspirate the AIM medium and wash the cells with 500 µL PBS.
   e. Add 300 µL Accutase per well and incubate the cells at 37°C for 3 min.

   △ CRITICAL: Extended exposure (>3 min) to Accutase will lead to decreased cell viability.
   f. Detach the cells from the plates and dissociate them into single cells by manual pipetting about ten times.
   g. Collect all cell suspensions from all wells in a 15-mL tube and add DMEM/10% FBS up to 1.5 mL/well in the 4-well plates to stop the Accutase activity.
   h. Centrifuge the cells at 200×g for 5 min and aspirate the medium.
   i. After cell counting, replate the cells at a density of 1.0 × 10^5 cells/cm² in a Geltrex-coated 24-well plate with 500 µL AIM medium containing 10 µM Y-27632 and incubate at 37°C for an additional 24 h.

   Note: Immunostaining analysis for GATA3, LHX1 and PAX2 can be performed to confirm AIM induction 72 h later. (Figure 1D). AIM cells co-express these three markers.

5. ND elongation (Figure 1C).
   a. Prepare 2 mL ND medium to correspond to two wells of a 24-well plate before starting this step.
   b. Wash the AIM cells with 500 µL PBS and add 1 mL ND medium per well of the 24-well plate.
   c. Incubate the cells at 37°C for 2 days without a medium change.
Note: Immunostaining analysis for RET can be performed to confirm ND elongation cell induction. ND elongation cells co-express RET and GATA3 (Figure 1E).

**iUB organoid induction in 3D culture**

ου Timing: 2 days for ND epithelialization and 6 days for iUB organoid induction

ου Timing: 6 days for the reconstitution of iUB organoids

This section describes the induction of iUB organoids through ND epithelialization step and reconstitution of iUB organoids from separated tip regions of iUB organoids.

6. ND epithelialization (Figure 1C).
   a. Prepare 2 mL ND medium for 20 wells of a 96-well plate before starting this step.
   b. Wash the ND cells with 500 μL PBS per well and then aspirate the PBS.
   c. Add 300 μL Accutase per well and incubate at 37°C for 3 min.
   d. Detach the cells from the plates and dissociate them into single cells by manual pipetting about ten times.
   e. Collect all cell suspensions in a 15-mL tube and add DMEM/10% FBS up to 1.5 mL/well in the 24-well plates to stop the Accutase activity.
   f. Centrifuge the cells at 200 g for 5 min and aspirate the medium.

   **Note:** You can cryopreserve these cells at a density of up to 2 × 10^6 cells/mL with STEMCELL BANKER.

   g. After resuspending the cells in ND medium and cell counting, seed the cells at a density of 1 × 10^4 cells/well in low-attachment M-bottom 96-well plates with 100 μL ND medium plus 10 μM Y-27632 and incubate the cells at 37°C for an additional 2 days without a medium change.

   **Note:** After two days, one ND aggregate including unwanted cells is formed per one well of 96-well culture plates.

7. iUB organoid induction (Figure 1C).
   a. Prepare 2 mL UB organoid medium for 20 wells of a 96-well plate before starting this step.
   b. Separate unwanted cells from ND aggregates by manual pipetting 10–20 times using a 10- or 200-μL pipette (Mae et al., 2018) (Figure 1F).

   **Note:** Unwanted cells are not UB lineage and arise in the process of UB differentiation because the induction rate of ND cells is not 100%. We recommend separating these unwanted cells to purify ND cells. The ND cell region is larger and harder than unwanted regions in one aggregate per well (Figure 1F).

   **Note:** If unwanted cells cannot be separated from the ND aggregate, reinduce the ND cells from hiPSCs by improving the APS induction step. Refer to troubleshooting 2.

   c. Aspirate ND medium and add 100 μL organoid medium per well to the same 96-well plates.
   d. Incubate the aggregates at 37°C for 6 days. Organoid medium is changed every two days to generate iUB organoids (Figures 1G–1I).

   **Note:** iUB organoids will be floating in the well. One iUB organoid is formed per well of the 96-well plates.
CRITICAL: Excessive pipetting (over 30 times) will break ND aggregates and may decrease UB budding.

Note: M-bottom 96-well plates with spindle-shaped bottoms are recommended to generate iUB organoids. It is difficult to generate ND cell aggregates with U-bottom 96-well plates and to observe cell aggregates by microscopy with V-bottom 96-well plates.

Note: You may centrifuge M-bottom 96-well plates containing ND cells at 200 x g for 2 min to promote the cell aggregate formation.

Note: The induction rate of iUB organoids may be low if the budding regions of iUB organoids are reduced and/or thickened. Refer to troubleshooting 3.

Additional: Reconstitution of iUB organoids from separated tip regions of iUB organoids.

- Prepare 2 mL UB organoid medium before starting this step.
- Move some iUB organoids to a 35-mm dish (Sumitomo Bakelite) with 2 mL Essential 6 medium.
- Prepare two 22G needles (Terumo, # NN-2225R) and a stereomicroscope.
- Manually separate the UB tip regions from iUB organoids with two needles using a stereomicroscope (Figure 1J).
- Move one separated UB tip region into one well of the low-attachment M-bottom 96-well plates and add 100 μL UB organoid medium per well.
- Incubate the aggregate at 37°C for 14 days. Organoid medium is changed every two days to generate iUB organoids (Figure 1K).

Note: This reconstitution process can be repeated 3–4 times for each tip.

2D-CDP induction

- Timing: 7 days for UB tip colony induction and 7 days for CDP induction

This section describes the induction of CDPs in 2D culture from iUB organoids through UB tip colonies.

8. UB tip colony induction (Figure 2A).
   - Prepare 600 μL UB tip medium for two wells of a 48-well plate before starting this step.
   - Coat the 48-well plate with 150 μL/well hydrogel.

   Note: Keep Matrigel and hydrogel on ice to prevent them from solidifying before use. For details, refer to materials and equipment.

   - Incubate the plate to solidify the hydrogel at 37°C for 1 h.
   - Collect 10 day 6 iUB organoids in a 1.5 mL tube.
   - Wash the organoids with 500 μL PBS twice.
   - Aspirate PBS and add 100 μL Accutase. Incubate at 37°C for 5 min.
   - Add 900 μL DMEM/F12 containing 10% FBS and dissociate the organoids by manual pipetting about 30 times.
   - Centrifuge the cells at 200 x g for 5 min and aspirate the medium.
   - After resuspending the cells in 100 μL UB tip medium and cell counting, seed the cells at a density of 5 x 10^4 cells/cm² in 48-well plates and add UB tip medium up to 300 μL per well.
   - Incubate the cells at 37°C for 7 days. Change the medium every two days.

   Note: After 7 days, 500–1,000 tip colonies 80–100 μm in diameter will be formed per well.
**Immunostaining analysis for RET and GATA3 will help confirm the tip colony induction (Figures 2B and 2C). Tip colonies co-express these markers.**

**Note:** If UB tip colonies cannot be formed, refer to troubleshooting 4.

**9. 2D-CDP induction (Figure 2A).**

a. Prepare 1 mL CDP medium for two wells of a 24-well plate before starting this step.

b. Aspirate the medium of day 7 UB tip colonies in 48-well plates (see 8. UB tip colony induction of step-by-step method details) and add 300 μL Cell Recovery Solution per well.

c. Incubate the plate at 4°C for 1 h to dissolve hydrogel containing 50% Matrigel.

d. Collect all cell suspension from the four wells of the 48-well plates into a 1.5 mL tube, centrifuge the colonies at 500 × g for 5 min and aspirate the supernatant.

**Note:** If the hydrogel remains around the UB tip colonies, we recommend adding 1 mL Cell Recovery Solution to the 1.5 mL tube after aspirating the supernatant. Pipet gently three to four times and incubate the cells at 4°C for an additional 1 h.

e. Wash the cell pellet in the 1.5 mL tube with 1 mL PBS and centrifuge the colonies at 500 × g for 5 min.
f. Aspirate PBS and add 100 µL Accutase in the 1.5 mL tube containing the UB tip colonies. Incubate the cells at 37°C for 5 min.
g. Add 900 µL DMEM/F12 containing 10% FBS per well and dissociate the colonies by manual pipetting until obtaining a single cell suspension.
h. Centrifuge the cells at 200×g for 5 min and aspirate the medium.
i. After resuspending the cells in 100 µL CDP medium and cell counting, seed the cells at a density of 5 × 10⁴ cells/cm² in 24-well plates with 500 µL CDP medium containing 10 µM Y-27632 and 0.125 µg/cm² iMatrix-511 silk.

**Note:** We add iMatrix-511 silk to the medium to coat the plate. You may precoat the plate with iMatrix-511 silk at 37°C for 1 h; however, this is a time-consuming process (Miyazaki et al., 2017.).

j. Incubate the cells at 37°C for 7 days. Change CDP medium every two days.

**Note:** Immunostaining analysis for FOXA1 and AQP2 will help confirm CDP induction (Figure 2D). CDPs co-express these markers.

**Note:** If the induction rate of CDPs is low, refer to troubleshooting 5.

### 3D-CDP organoid induction

© Timing: 14 days for reconstitution of iUB organoids and 14 days for 3D-CDP induction

This section describes the induction of CDPs in 3D culture from UB tip colonies through reconstituted iUB organoids.

10. Reconstitution of iUB organoids from tip colonies (Figure 2A).
   a. Prepare 2 mL iUB organoid medium to correspond to 10 reconstituted iUB organoids before starting this step.
   b. Aspirate the medium of day 7 UB tip colonies (after finishing 8. UB tip colony induction of step-by-step method details) and add 300 µL Cell Recovery Solution per well.
   c. Incubate the cells at 4°C for 1 h to dissolve the hydrogel.
   d. Collect all colony suspensions in a 15-mL tube, centrifuge the cells at 500×g for 5 min and aspirate the supernatant.

**Note:** If the hydrogel remains around the UB tip colonies, we recommend adding 5 mL Cell Recovery Solution and incubating the cells at 4°C for an additional 1 h.

   e. Wash the colonies with 5 mL PBS twice.
   f. After resuspending the colonies in 2 mL iUB organoid medium, seed the colonies from 10 wells of 48-well plates to one low-attachment 35 mm dish.
   g. Incubate the colonies at 37°C for 14 days. Change iUB organoid medium every two days.

**Note:** Immunostaining analysis for RET and CK8 may help confirm iUB organoid reconstitution (Figure 2E). The tip and trunk regions of reconstituted iUB organoids express RET and CK8, respectively.

11. 3D-CDP organoid induction (Figure 2A).
   a. Prepare 1 mL CDP medium for 10 3D-CDP organoids before starting this step.
b. Aspirate the medium of day 14 reconstituted iUB organoids (after finishing 10. Reconstitution of iUB organoids from tip colonies of step-by-step method details) and wash the organoids with 2 mL PBS.

c. Aspirate PBS and add 2 mL CDP medium.

d. Incubate the cells at 37°C for 14 days. Change CDP medium every two days.

**Note:** Immunostaining analysis for FOXA1 and AQP2 will help confirm 3D CDP organoids induction (Figure 2F). 3D CDP organoids co-express these markers.

### EXPECTED OUTCOMES

The most important outcomes of these protocols include the induction of iUB organoids that have the potential for repeated branching morphogenesis, UB tip colony expansion and CDP differentiation. Immunostaining analysis is a useful method to evaluate the quality of the iUB organoids, UB tip colonies and CDPs. High quality iUB organoids express not only a basal marker, LAMININ, but also an apical marker, EZRIN, indicating that they have apicobasal polarity and tubular lumens (Figure 1H). Additionally, immunostaining for RET and CK8 is important for confirming the formation of the UB tip and trunk domains, respectively (Figure 1I). Immunostaining for RET and GATA3 and for FOXA1 and AQP2 will help confirm the induction of tip colonies (Figure 2C) and CDPs (Figures 2D and 2F), respectively.

These iUB organoids are suitable for the generation of disease models for congenital anomalies of the kidney and urinary tract (CAKUT). For example, we developed a disease model for multicystic dysplastic kidney (MCDK) using our iUB organoids and heterozygous HNF1α-knockout hiPSC lines established by the CRISPR-Cas9 system (Bellanne-Chantelot et al., 2004; Heidet et al., 2010; Nakayama et al., 2010; Mae et al., 2020). These HNF1α+/− iUB organoids exhibited fewer tip regions and faint apicobasal polarity, similar to the findings in MCDK model mice (Lokmane et al., 2010; Desgrange et al., 2017; Mae et al., 2020).

Thus, our iUB organoid system is valuable for generating in vitro CAKUT models and for elucidating the developmental mechanisms of UB branching and collecting duct maturation.

### LIMITATIONS

Our iUB organoids have some limitations. First, the absence of reciprocal interactions between hiPSC-derived nephron progenitors (NPs) and our iUB organoids prevents extensive branching morphogenesis of the iUB organoids and differentiation of the NPs into nephron structures in co-culture conditions (Mae et al., 2020). The absence of interactions may be caused by the functional immaturity of the hiPSC-derived NPs and iUB organoids or differences in the developmental stages between the NPs and iUB organoids.

Another limitation of our iUB organoid system is the difficulty in inducing mature collecting duct cells. Our CDPs are equivalent to their in vivo counterparts in human GW7-8 embryos (Wang et al., 2018). However, the branching morphogenesis of UB is repeated until GW15 or later in human embryonic kidneys (Costantini and Kopan, 2010; Potter, 1972; Osathanondh and Potter, 1963). Therefore, our iUB organoid system cannot be used to generate disease models for some types of CAKUT, especially cystic kidney diseases, because cystogenesis begins after collecting duct maturation.

### TROUBLESHOOTING

**Problem 1**

Difficulty in inducing APS cells (step 3).
You may need to optimize the treatment time of Activin A and CHIR99021 because the time required for APS induction varies among hiPSC lines. Immunostaining analysis for BRACHYURY and SOX2 will help confirm the appropriate APS induction. APS cells will express BRACHYURY but not SOX2 (Figure 3A). The APS induction time is from 16 to 28 h. If the APS induction time is too short, SOX2-positive cells will remain in the center of the colonies (Figure 3B).

Problem 2
When unwanted cells are separated from ND aggregates with manual pipetting, the aggregates break (step 7; Figure 3C).
Potential solution
The induction rate of ND cells may be low (Figures 3D and 3E). You may reinduce ND cells from hiPSCs by improving the APS induction step (see troubleshooting 1).

Problem 3
Budding regions of iUB organoids are reduced and/or thickened (step 7; Figure 3F).

Potential solution
Matrigel concentrations may be too low to form the apicobasal polarity and tubular lumen of iUB organoids. You can increase the concentration of Matrigel up to 10% vol in the iUB organoid induction step. You should gradually increase the concentration of Matrigel.

Problem 4
No tip colonies are formed on the hydrogel (step 8; Figure 3G).

Potential solution
The hydrogel layer may be too thin or the concentration of Matrigel may be too low to form tip colonies. Add up to 500 μL hydrogel to the 48-well plates or increase the concentrations of Matrigel up to 75% in the UB tip colony induction step.

Problem 5
Failure to induce CDPs (step 9).

Potential solution
When tip colonies look like halos (Figure 3H), their induction rate may be too low. Shorten the tip colony induction time to 5 days to increase the induction efficiency in the UB tip colony induction step.

RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Kenji Osafune (osafu@cira.kyoto-u.ac.jp).

Materials availability
This study did not generate new unique reagents.

Data and code availability
No new codes have been generated.

ACKNOWLEDGMENTS
This study was partially supported by Otsuka Pharmaceutical Co., Ltd., by the Japan Society for the Promotion of Science (JSPS) through its Grant-in-Aid for Scientific Research (B) (JSPS KAKENHI Grant Number 18H02826) to K.O. and Grant-in-Aid for Young Scientists (B) (JSPS KAKENHI Grant Number 17K15546) to S.-I.M., by iPS Academia Japan, Inc. through its 2018 iPS Academia Japan Grant to S.-I.M., by the Japan Agency for Medical Research and Development (AMED) through its research grant “Projects for Technological Development, Core Center for iPS Cell Research and The Acceleration Program for Intractable Diseases Research utilizing Disease-specific iPS cells, Research Center Network for Realization of Regenerative Medicine” and “Practical Research Project for Rare / Intractable Diseases” to K.O., and by AMED through its research grant “The Program for Technological Innovation of Regenerative Medicine” to S.-I.M.
AUTHOR CONTRIBUTIONS

M.R., S.-I.M., and K.O. designed the study. K.O. supervised the study. M.R., S.-I.M., and K.O. drafted the manuscript. All authors discussed the results and commented on the manuscript.

DECLARATION OF INTERESTS

M.R. is paid by Rege Nephro Co., Ltd. S.-I.M. is a scientific advisor of Rege Nephro Co., Ltd. K.O. is a founder and member of the scientific advisory boards of iPS Portal, Inc., and a founder and chief scientific advisor of Rege Nephro Co., Ltd. The differentiation methods for iUB organoids from hiPSCs (US62/587693; PCT/JP2020/037329).

REFERENCES

Bellanne-Chantelot, C., Chauveau, D., Gautier, J.F., Dubois-Laforgue, D., Clauin, S., Beaufils, S., Wilhelm, J.M., Boitard, C., Noel, L.H., Velho, G., et al. (2004). Clinical spectrum associated with hepatocyte nuclear factor-1beta mutations. Ann. Intern. Med. 140, 510–517.

Costantini, F., and Kopan, R. (2010). Patterning a complex organ: branching morphogenesis and nephron segmentation in kidney development. Dev. Cell 18, 698–712. https://doi.org/10.1016/j.devcel.2010.04.008.

Desgrange, A., Heliot, C., Skovorodkin, I., Akram, S.U., Heikkila¨ , J., Ronkainen, V.P., Miinalainen, I., Vainio, S.J., and Cereghini, S. (2017). HNF1B controls epithelial organization and cell polarity during ureteric bud branching and collecting duct morphogenesis. Development 144, 4704–4719. https://doi.org/10.1242/dev.154336.

Heidet, L., Decramer, S., Pawtowski, A., Morinière, V., Bandin, F., Knebelmann, B., Lebre, A.S., Fagué, S., Guigonis, V., Antignac, C., and Salomon, R. (2010). Spectrum of HNF1B mutations in a large cohort of patients who harbor renal diseases. Clin. J. Am. Soc. Nephrol. 5, 1079–1090. https://doi.org/10.2215/cjn.06810909.

Lokmane, L., Heliot, C., Garcia-Villalba, P., Fabre, M., and Cereghini, S. (2010). vHNF1 functions in distinct regulatory circuits to control ureteric bud branching and early nephrogenesis. Development 137, 347–357. https://doi.org/10.1242/dev.042226.

Mae, S.I., Ryosaka, M., Sakamoto, S., Matsuse, K., Nozaki, A., Igarashi, K., Kabai, R., Watanabe, A., and Osafune, K. (2020). Expansion of human iPSC-derived ureteric bud organoids with repeated branching potential. Cell Rep. 32, 107963. https://doi.org/10.1016/j.celrep.2020.107963.

Mae, S.I., Ryosaka, M., Toyoda, T., Matsuse, K., Oshima, Y., Tsujimoto, H., Okumura, S., Shibasaki, A., and Osafune, K. (2018). Generation of branching ureteric bud tissues from human pluripotent stem cells. Biochem Biophys Res Commun 495 (1), 954–961, In press. https://doi.org/10.1016/j.bbrc.2017.11.105.

Miyazaki, T., Isobe, T., Nakatsuji, N., and Suemori, H. (2017). Efficient adhesion culture of human pluripotent stem cells using laminin fragments in an uncoated manner. Sci. Rep. 7, 41165. https://doi.org/10.1038/srep41165.

Nakayama, M., Nozu, K., Goto, Y., Kamei, K., Ito, S., Sato, H., Emi, M., Nakanishi, K., Tsuchiya, S., and Iijima, K. (2010). HNF1B alterations associated with congenital anomalies of the kidney and urinary tract. Pediatr. Nephrol. 25, 1073–1079. https://doi.org/10.1007/s00467-010-1454-9.

Osathanondh, V., and Potter, E.L. (1963). Development of human kidney as shown by microdissection. II. Renal pelvis, calyces, and papillae. Arch. Pathol. 76, 277–289.

Potter, E.L. (1972). Normal and Abnormal Development of the Kidney (Year Book Medical Publishers).

Wang, P., Chen, Y., Yong, J., Cui, Y., Wang, R., Wen, L., Qiao, J., and Tang, F. (2018). Dissecting the global dynamic molecular profiles of human fetal kidney development by single-cell RNA sequencing. Cell Rep. 24, 3554–3567.e3. https://doi.org/10.1016/j.celrep.2018.08.056.